Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses
This Frontiers in Pharmacology article investigates how using different time-averaged exposure metrics, specifically the time-averaged…
CertaraJanuary 21, 2025
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region
The integration of MID3 offers a transformative opportunity for the MENA region to advance pharmaceutical…
CertaraJanuary 14, 2025
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)
In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…
CertaraJanuary 9, 2025
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease
The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…
CertaraJanuary 8, 2025
From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations
SVP, Client and Regulatory Strategy, Certara Dr. Karen Rowland Yeo is Senior Vice-President, Client &…
CertaraJanuary 3, 2025
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation
This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…
CertaraDecember 9, 2024
PK/PD Data Analysis, Concepts and Applications eBook
Accelerate your Journey: Learn & Grow with the Standard Book for PK Scientists
CertaraNovember 25, 2024
